About Anavex Life Sciences Corp.
https://www.anavex.comAnavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases.
CEO
Christopher U. Missling
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2015-10-07 | Reverse | 1:4 |
ETFs Holding This Stock
Summary
Showing Top 3 of 109
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:7.19M
Value:$34.65M
BLACKROCK INC.
Shares:6.39M
Value:$30.81M
VANGUARD GROUP INC
Shares:5.1M
Value:$24.6M
Summary
Showing Top 3 of 213
About Anavex Life Sciences Corp.
https://www.anavex.comAnavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $14.46M ▲ | $-13.24M ▼ | 0% | $-0.16 ▼ | $-13.37M ▼ |
| Q2-2025 | $0 | $12.51M ▼ | $-11.2M ▲ | 0% | $-0.13 ▲ | $1.13M ▲ |
| Q1-2025 | $0 | $13.59M ▼ | $-12.11M ▼ | 0% | $-0.14 | $-11.47M ▲ |
| Q4-2024 | $0 | $14.34M ▼ | $-11.62M ▲ | 0% | $-0.14 | $-34.02M ▼ |
| Q3-2024 | $0 | $14.73M | $-12.21M | 0% | $-0.14 | $-12.27M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $101.16M ▼ | $102.43M ▼ | $11.47M ▼ | $90.96M ▼ |
| Q2-2025 | $115.77M ▼ | $117.14M ▼ | $17.38M ▲ | $99.76M ▼ |
| Q1-2025 | $120.78M ▼ | $124.04M ▼ | $13.13M ▼ | $110.92M ▼ |
| Q4-2024 | $132.19M ▼ | $135.57M ▼ | $15.3M ▲ | $120.26M ▼ |
| Q3-2024 | $138.76M | $141.53M | $11.75M | $129.78M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-13.24M ▼ | $-12.46M ▼ | $0 | $-2.14M ▼ | $-14.61M ▼ | $-12.46M ▼ |
| Q2-2025 | $-11.2M ▲ | $-5.86M ▲ | $0 | $852K ▲ | $-5M ▲ | $-5.86M ▲ |
| Q1-2025 | $-12.11M ▼ | $-12.12M ▼ | $0 | $708K ▲ | $-11.41M ▼ | $-12.12M ▼ |
| Q4-2024 | $-11.62M ▲ | $-6.66M ▼ | $0 | $89K ▼ | $-6.57M ▼ | $-6.66M ▼ |
| Q3-2024 | $-12.21M | $-5.18M | $0 | $4.55M | $-630K | $-5.18M |
CEO
Christopher U. Missling
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2015-10-07 | Reverse | 1:4 |
ETFs Holding This Stock
Summary
Showing Top 3 of 109
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:7.19M
Value:$34.65M
BLACKROCK INC.
Shares:6.39M
Value:$30.81M
VANGUARD GROUP INC
Shares:5.1M
Value:$24.6M
Summary
Showing Top 3 of 213